Weight Loss & Metabolic / side effects and safety / Last reviewed 2026-04-04

Liraglutide Side Effects: Safety Signals and Warnings

Liraglutide safety concerns are compound-specific. The main listed side effects are Nausea, Vomiting, and Diarrhea. The main warning signals are Boxed warning: thyroid C-cell tumors in rodents, Pancreatitis risk, and Contraindicated with MTC history.

Read the full Liraglutide guide Browse answer pages

Direct Answer

Liraglutide is FDA-approved for type 2 diabetes (Victoza) and obesity (Saxenda), with Phase 3 RCT data (SCALE trial) showing 8-9% body weight reduction - meaningful but less than semaglutide or tirzepatide. It is well-characterized with a long safety record. For weight management research where once-daily dosing is acceptable, liraglutide is a solid, established reference compound.

Evidence grade
Level A
Research status
FDA Approved
Category
Weight Loss & Metabolic
Best for
Obesity, type 2 diabetes, weight management research, GLP-1 reference compound

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Prescription required. Widely available globally.

Evidence Snapshot

Evidence gradeLevel A
Research statusFDA Approved
Best supported outcomesWeight Loss (Level A), Blood Sugar Control (Level A), and Cardiovascular Protection (Level A)
Primary citation count2
Last reviewed2026-04-04

Related Guides

How to Cite This Page

ExaminePeptides. "Liraglutide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/liraglutide-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.